It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...
MedPage Today on MSN1d
Over 50% of U.S. Adults Qualify for Ozempic, WegovyMore than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.
TipRanks on MSN15h
iX Biopharma’s iXB 401: A Breakthrough in Drug DeliveryX Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...
Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...
Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...
DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...
The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a ...
The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation ...
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
Dallas Morning News on MSN12d
FDA adds new warning to weight loss drugs including WegovyThe FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback